オプションチェーンは、Riot Platformsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Riot Platformsの市場センチメントを評価します。.

Riot Platforms (NASDAQ:RIOT) 株価情報, オプションチェーン

RIOT PLATFORMS INC

Riot Platforms

Riot Platforms Inc is a vertically integrated Bitcoin mining company focused on building, supporting, and operating blockchain technologies. The company's segments include Bitcoin Mining and Engineering. The Bitcoin Mining segment generates revenue from the Bitcoin the Company earns through its Bitcoin Mining activities. The Engineering segment generates revenue through customer contracts for custom engineered electrical products. It generates the majority of its revenue from the Bitcoin Mining segment.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

Markets

$BTC

BITF

RIOT

最近、ビットコイン（仮想通貨：BTC）マイニング会社ライオットプラットフォーム（NASDAQ:RIOT）は、ライバル企業ビットファーム（NASDAQ:BITF）に対する持ち株比率を12%に引き上げました。

ライオットプラットフォームがビットファームの持ち株比率増加

Riot Platforms Inc

Several exemptions exist among President Donald Trump&#8216;s <a href="https://www.benzinga.com/markets/25/04/44621408/market-access-has-a-price-trump-unveils-list-of-tariffs-countries-targeted" target="_blank" rel="noopener">broad tariffs</a>, which were announced on Wednesday. 
The biopharma industry has historically been shielded from tariffs, including during Trump&#8217;s first term. Given its significant manufacturing presence in Europe, investors had feared global tariffs could disrupt the sector.
Morningstar <a href="https://www.morningstar.com/stocks/biopharma-industry-exempt-global-10-tariff-we-still-see-margin-tax-rate-risks" target="_blank" rel="noopener">reports</a> that with the U.S. importing approximately $200 billion in pharmaceuticals in 2024, a 10% tariff could have cost the industry $20 billion, with some of the largest firms facing annual tariffs of up to $1 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44642463/french-president-macron-suggests-suspension-of-eu-investments-in-us-amid-tariff-turmoil" rel="noreferrer noopener">French President Macron Suggests Suspension Of EU Investments In US Amid Tariff Turmoil, Vows &#8216;More Powerful&#8217; Response</a>
Goldman Sachs expects continued volatility in the biotechnology sector (XBI and S&amp;P 500 are down about 14% and 7% year-to-date, respectively), driven by broader economic <a target="_blank" href="https://www.benzinga.com/news/global/25/04/44631606/trumps-tariff-exemptions-include-semiconductors-pharmaceuticals-oil-and-more" rel="noreferrer noopener">uncertainty and unclear healthcare policy</a>.
Analyst Salveen Richter has analyzed geographic exposure and tax rates for individual companies and sees Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) and Alnylam Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) in the strongest position, followed by Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) and Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>).
Regeneron Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) raises some concerns due to its significant presence in Ireland. If tariffs are applied, they would likely increase the cost of goods sold since companies often import ingredients or finished products into the U.S.
Analyst Richter adds that <a target="_blank" href="https://www.benzinga.com/quote/AMGN" rel="noreferrer noopener">Amgen</a>, <a target="_blank" href="https://www.benzinga.com/quote/ALNY" rel="noreferrer noopener">Alnylam</a>, <a target="_blank" href="https://www.benzinga.com/quote/BIIB" rel="noreferrer noopener">Biogen</a>, and <a target="_blank" href="https://www.benzinga.com/quote/REGN" rel="noreferrer noopener">Regeneron</a> are the least exposed to Medicaid risk.
Goldman Sachs said Friday that it&#8217;s been hard to measure the exact impact of potential tariffs on U.S. biopharma due to limited public data on where drugs are made.
Their analysis shows limited manufacturing exposure to Canada, Mexico and China. Pharmaceuticals from Canada and Mexico are also likely exempt under the USMCA trade deal. However, some companies do rely heavily on manufacturing in the EU.
If tariffs are placed on drugs made outside the U.S. and kept in place, they could raise manufacturing costs. Companies often import ingredients or finished products before selling them in the U.S. Some manufacturers are reportedly speeding up shipments from Europe out of concern that tariffs may apply to <a href="https://www.benzinga.com/general/biotech/25/03/44440233/pharmaceutical-firms-say-uk-investment-is-unlikely-unless-payment-levy-is-adressed" target="_blank" rel="noopener">those products,</a><a href="https://www.benzinga.com/general/biotech/25/03/44440233/pharmaceutical-firms-say-uk-investment-is-unlikely-unless-payment-levy-is-adressed" target="_blank" rel="noreferrer noopener"> too</a>.
Goldman Sachs is also watching for exceptions or phased rollouts, pointing to a similar eight-year grace period in the Biosecure Act.
Still, the analyst writes that biopharma companies are generally resilient due to their high profit margins and globally spread operations.
Companies that produce small-molecule drugs might handle a U.S. manufacturing shift better than those making biologics since small molecules require less complex production.
Senator Ron Wyden has raised concerns about Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) using offshore setups to reduce U.S. taxes.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/04/44648087/karman-strikes-90m-deal-for-mti-enhancing-position-in-next-gen-defense-technologies" target="_blank" rel="noreferrer noopener">Karman Strikes $90M Deal For MTI, Enhancing Position In Next-Gen Defense Technologies</a></li>
</ul>
Photo: Shutterstock

Biotech

Government

Large Cap

Health Care

General

ALNY

AMGN

BIIB

GILD

REGN

VRTX

Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks

To <a href="https://www.benzinga.com/markets/25/03/44533852/what-would-buffett-do-with-markets-inches-away-from-the-extreme-fear-zone-is-it-finally-time-to-be-greedy">paraphrase</a> legendary investor Warren Buffett, a market participant should acquire shares of good companies that find themselves in temporarily bad circumstances. 
Under this framework, consumer technology giant Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) ought to rank as a tremendous buying opportunity amid the Wall Street bloodbath. Long-term data suggests that it is indeed an opportunity — but as a trader, timing matters.
Following the close of the midweek session, President Donald Trump announced <a href="https://www.benzinga.com/25/04/44613907/tariff-shock-incoming-as-trump-prepares-sweeping-trade-duties-what-traders-need-to-know">sweeping new trade tariffs</a>, an event he termed "Liberation Day." The initiative is a symbolic push to tackle the ballooning U.S. trade deficit <a href="https://www.benzinga.com/topic/tariffs">with major global partners</a>. Unfortunately, the levies were steeper than analysts expected, <a href="https://www.benzinga.com/government/regulations/25/04/44631916/wall-street-wipes-out-2-trillion-apple-eyes-worst-day-since-covid-19-pandemic-oil-plummets-whats-driving-markets-thursday">sending shockwaves through global markets</a> on Thursday.
Even as the Street digested the news and the broader implications, one day of extreme volatility wasn't enough, with Friday being subjected to another crimson tide. Prominent <a href="https://www.benzinga.com/general/market-summary/25/04/44643100/us-stocks-likely-to-open-lower-after-the-worst-selloff-since-2020-tariff-announcement-was-100-smoot-hawley-disguised-as-thoughtful-policy-says-expert">experts voiced their displeasure</a> at the tariffs, warning about severe consequences stemming from decelerated economic activity.
Still, amid the social media uproar, there was one point that stood out. Creative Planning Chief Market Strategist Charlie Bilello remarked that while the VIX or the so-called fear index reached its highest closing level since August 2024, the S&amp;P 500 has historically delivered "higher than average" returns following significant surges in volatility.
Since Apple stock is a benchmark security — leveraging a tremendous influence on both the tech ecosystem and the wider equities space — it stands to reason that its present volatility is a long-term buying opportunity. After all, one wouldn't naturally expect a giant like Apple to be permanently deflated.
From a patient investor's perspective, the red ink serves as a potential time machine — a chance to hop on the train that was previously missed. But from a trader's perspective, diving into Applr stock now may not be the most prudent decision.
<h1 class="wp-block-heading">The Death Cross in AAPL Stock is Warning First, Then Opportunity</h1>
To be sure, opportunistic traders will find it difficult to avoid reacting greedily to the hemorrhaging. Adding to the contrarian fervor, Apple stock is on the absolute cusp of printing the dreaded <a href="https://www.benzinga.com/trading-ideas/technicals/25/04/44629335/apple-stock-slammed-by-trump-tariffs-is-a-death-cross-next">death cross</a> — a technical sign when a security's 50-day moving average crosses below its 200 DMA.
On paper, the death cross represents a warning, marking the beginning of a serious downcycle or even an outright bear market. For many investors, it may symbolize the last chance to exit shares or take protective measures through advanced options strategies before further volatility erupts.
On the other hand, there's also the contrarian thought process that when the death cross flashes, much (if not most) of the bad news has already been baked in. Therefore, it's possible, if not likely, that the technical indicator could be a buying signal.
Here's the thing about Apple stock: while its death cross statistically represents a compelling buying opportunity, in the near term, the indicator should be interpreted at face value.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04150515/AAPL-stock-death-cross-returns-1024x576.jpg" alt="" class="wp-image-858378" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04150515/AAPL-stock-death-cross-returns-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04150515/AAPL-stock-death-cross-returns-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04150515/AAPL-stock-death-cross-returns-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04150515/AAPL-stock-death-cross-returns.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by author</figcaption></figure>
More specifically, over the past decade, Apple stock printed five death crosses. Sure enough, three months to one year removed from this negative intersection, Apple has swung higher across these time intervals four out of five times (or 80%). However, at the one-month mark following the death cross, Apple has only risen one time — meaning that the failure rate pops to 80%.
From a statistical wide angle, it's difficult to analyze how Apple stock will respond given that extreme volatility is rare. Right now, the equity is on the verge of losing about 12% in the trailing five sessions. The last time Apple lost double-digit percentage points in a one-week period was in April 2016.
Pulling up a historical chart, one can see that the volatile event that took place a decade ago took several months to recover. And that's the lesson the death cross is broadcasting: yes, it is a buying opportunity but not right now.
<h1 class="wp-block-heading">Switch Hitting for the Agnostic Trader</h1>
Being a successful trader requires not being married to a specific direction and that's the opportunity available in Apple stock. With the current flashing of the death cross likely to result in near-term volatility, aggressive traders may first want to consider the 195/190 bear put spread for the options chain expiring May 2.
The above transaction involves buying the $195 put (at a time-of-writing ask of $1,225) and simultaneously selling the $190 put (at a bid of $970). Subsequently, the proceeds from the short put partially offset the debit paid for the long put, resulting in a net cash outlay of $255.
Should Apple fall to or below the short strike price at expiration, the maximum reward is the difference between the strike prices (multiplied by 100 shares) minus the cash outlay or $245 (a payout of 96%). This trade plays off the fact that the average one-month loss (assuming only the negative scenario) following the death cross is 1.06%.
For long-side traders, patience may be required. One compelling idea that stands out is the 215/220 bull call spread for the options chain expiring July 18. This trade plays on the rebound effect of the death cross while also respecting the time component. Executing this trade requires buying the $215 call and simultaneously selling the $220 call, with the aim that Apple will hit this latter price at expiration.

Photo: Shutterstock

Equities

Options

Movers

Tech

AAPL

Options Corner: Apple Flashs Contrarian Death Cross — But Wait For The Right Count

<h2>Maxeon Provides Strategic Business Update</h2>
PRNewswire
SINGAPORE, April 4, 2025 /PRNewswire/ -- Maxeon Solar Technologies, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAXN#NASDAQ">MAXN</a>), a global leader in solar innovation and channels, today provided an update on key business issues, recent transactions, and transformation initiatives.
"Maxeon continues to transform its business to compete more effectively in a challenging solar market, and delivering top-tier solar panels and renewable energy solutions to our customers for the long-term remains our highest priority," said George Guo, Maxeon CEO. "While the Company still faces near-term headwinds, we are making progress in strengthening our supply chain versatility and resilience, streamlining operations, increasing efficiency, and reducing cost. We are confident in the future of solar energy and in Maxeon's ability to best meet the needs of our growing U.S. partner and IPP network."
Maxeon focuses its energy on the U.S. solar market Maxeon has successfully concluded the previously announced transactions to strategically restructure its business portfolio and geographic market focus to concentrate exclusively on the U.S. market, where its presence and planned onshore manufacturing can create a strong platform to drive growth and success for the Company and its expanding network of partners.
As previously disclosed, Maxeon has sold certain non-U.S. assets, with proceeds to Maxeon's balance sheet of approximately $94 million dollars. These restructuring transactions have positioned Maxeon for the future, ensuring a clear focus on U.S. residential, commercial, and utility power plant markets.
&nbsp;

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

Maxeon Solar Technologies Provides Strategic Business Update; Focuses On U.S. Market, Completes $94M Non-U.S. Asset Sale, And Restructures Business To Strengthen Supply Chain And Drive Growth In Residential, Commercial, And Utility Solar Sectors

Management

EDSA

Edesa Biotech Appoints Peter Weiler As CFO; Succeeds Stephen Lemieux

Whales with a lot of money to spend have taken a noticeably bullish stance on Williams Companies.
Looking at options history for Williams Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) we detected 10 trades.
If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 40% with bearish.
From the overall spotted trades, 8 are puts, for a total amount of $434,943 and 2, calls, for a total amount of $269,576.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $40.0 to $60.0 for Williams Companies over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Williams Companies stands at 5967.5, with a total volume reaching 13,313.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Williams Companies, situated within the strike price corridor from $40.0 to $60.0, throughout the last 30 days.
<h3>Williams Companies Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743797735_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>WMB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$1.15</td>
<td>$1.1</td>
<td>$1.1</td>
<td>$60.00</td>
<td>$238.6K</td>
<td>14.9K</td>
<td>2.4K</td>
</tr>
<tr>
<td>WMB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/11/25</td>
<td>$3.2</td>
<td>$3.0</td>
<td>$3.1</td>
<td>$57.00</td>
<td>$145.7K</td>
<td>3.0K</td>
<td>2.9K</td>
</tr>
<tr>
<td>WMB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/11/25</td>
<td>$3.4</td>
<td>$2.1</td>
<td>$2.1</td>
<td>$57.00</td>
<td>$57.3K</td>
<td>3.0K</td>
<td>1.3K</td>
</tr>
<tr>
<td>WMB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/11/25</td>
<td>$2.2</td>
<td>$2.15</td>
<td>$2.15</td>
<td>$57.00</td>
<td>$53.7K</td>
<td>3.0K</td>
<td>1.6K</td>
</tr>
<tr>
<td>WMB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/11/25</td>
<td>$2.2</td>
<td>$2.15</td>
<td>$2.15</td>
<td>$57.00</td>
<td>$43.0K</td>
<td>3.0K</td>
<td>1.0K</td>
</tr>
</tbody>
</table>

<h3>About Williams Companies</h3>
Williams Companies is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
After a thorough review of the options trading surrounding Williams Companies, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Williams Companies</h3>
<ul>
<li>Trading volume stands at 18,923,491, with WMB's price down by -7.22%, positioned at $54.77.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 31 days.</li>
</ul>
<h3>What The Experts Say On Williams Companies</h3>
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $60.33.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on Williams Companies, maintaining a target price of $70. 
&#x2A; Maintaining their stance, an analyst from Scotiabank continues to hold a Sector Perform rating for Williams Companies, targeting a price of $53. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Equal-Weight rating on Williams Companies with a target price of $58. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Williams Companies with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Looking At Williams Companies's Recent Unusual Options Activity

Essential Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPRT#NYSE">EPRT</a>) has outperformed the market over the past 5 years by 8.82% on an annualized basis producing an average annual return of 22.6%. Currently, Essential Properties has a market capitalization of $5.77 billion. 
Buying $1000 In EPRT: If an investor had bought $1000 of EPRT stock 5 years ago, it would be worth $2,903.59 today based on a price of $30.72 for EPRT at the time of writing.
<h3>Essential Properties's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743797734_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

EPRT

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) on Thursday presented new data at the AD/PD 2025 International Conference on Alzheimer&#8217;s <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">and Parkinson&#8217;s Diseases</a>.
Highlights included presentations from the ongoing trontinemab Phase 1b/2a Brainshuttle AD study, which <a target="_blank" href="https://www.roche.com/media/releases/med-cor-2025-04-03" rel="noreferrer noopener">demonstrated</a> dose-dependent rapid amyloid depletion from the brain and the potential of the Elecsys pTau181 plasma test to rule out amyloid pathology.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44634689/sareptaroche-suspend-elevidys-gene-therapy-trials-in-europe-after-patient-death" rel="noreferrer noopener">Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death</a>
<ul>
<li>Preliminary results for trontinemab from 114 participants in the 1.8 or 3.6 mg/kg suggest a rapid and deep, dose-dependent reduction of amyloid plaques in the brain as measured by amyloid positron emission tomography (PET).</li>
<li>Amyloid plaques are extracellular deposits of aggregated amyloid beta peptides (Aβ) that are a hallmark of Alzheimer&#8217;s disease, disrupting brain function and contributing to cognitive decline.</li>
<li>Trontinemab reduced amyloid levels below the 24 centiloid threshold in 81% of participants (n=21/26) in the 3.6 mg/kg dose group after 28 weeks.</li>
<li>These data were reinforced by early and significant reductions in fluid biomarkers of Alzheimer&#8217;s disease, including total tau, phosphorylated Tau (pTau)181, pTau217, and neurogranin measured in cerebrospinal fluid and plasma.</li>
</ul>
Trontinemab continues to show a favorable safety and tolerability profile. Amyloid-related imaging abnormalities-edema/effusion (ARIA-E) were observed in &lt;5% (n=3/114) of participants (blinded data), which were radiographically mild, and there was one case associated with mild symptoms.
Trontinemab is currently being studied in the Phase Ib/IIa Brainshuttle AD study assessing the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of trontinemab in participants with Alzheimer&#8217;s disease.
Roche also announced that it would initiate a Phase 3 program for trontinemab, which is expected later this year.
Results from 604 participants in a multicentre study of Roche&#8217;s Elecsys pTau181 plasma test were presented, demonstrating its potential to accurately rule out amyloid pathology, a hallmark of Alzheimer&#8217;s disease, in people with cognitive impairment.
Roche anticipates tests being available in Europe by late 2025, with the U.S. following.
Price Action: RHHBY stock closed lower by 4.37% to $37.65 on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/buybacks/25/04/44647720/matador-resources-sells-eagle-ford-assets-announces-potential-buybacks" target="_blank" rel="noreferrer noopener">Matador Resources Sells Eagle Ford Assets, Announces Potential Buybacks</a></li>
</ul>
Photo by OleksSH via Shutterstock

RHHBY

Roche To Start Phase 3 Study For Alzheimer's Prospect This Year After New Data From Phase 2

WIIM

CHSN

Chanson International Holding shares are trading higher after the company reported a year-over-year increase in FY24 financial results.

Earnings

Guidance

Chanson International Holding FY24 EPS $0.05 Up From $0.03 YoY; Revenue $18.2M Up From $17.3M YoY

CIFR

Cipher Mining Announced March 2025 BTC Mined 210

Artesian Water Company, Inc. ("Artesian"), a subsidiary of Artesian Resources Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTNA#NASDAQ">ARTNA</a>), filed an application with the Delaware Public Service Commission (PSC) today for a change in customer rates. The rate application submitted to the PSC for review and approval consists of a requested increase in revenue of 12.41%, or approximately $10.8 million, on an annualized basis. The increase also reflects the recovery of investments made under the Distribution System Improvement Charge (DSIC) of 1.66% currently in place that will reset to 0.0% once new base rates are implemented, meaning the incremental increase to existing billed rates would be 10.75%. This rate filing will undergo extensive review by both the PSC and the Division of the Public Advocate (DPA).
The request addresses investments in water utility infrastructure made by Artesian since October 1, 2023 and projected to be made through September 30, 2025. It also addresses increases in costs necessary to provide reliable service while continuing to maintain compliance with more stringent water quality regulations.

ARTNA

Artesian Water Company Files Rate Application With Delaware Public Service Commission Seeking 12.41% Revenue Increase, Or $10.8M Annually, To Address Infrastructure Investments And Rising Costs

American Vanguard Gets NYSE Notice Regarding Delayed 10-K Filing

Stock Split

CPHI

China Pharma Holdings To Implement 1-For-10 Reverse Stock Split, Effective April 15, 2025

Quest Resource Holding Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRHC#NASDAQ">QRHC</a>) ("Quest" or the "Company"), a national leader in environmental waste and recycling services, today announced the sale of its tenant-direct portion of the RWS commercial property management business.
The Company agreed to sell the client contracts to Lincoln Waste Solutions, a part of Reconomy, a leading international specialist in the circular economy. The total consideration for the sale was approximately $5 million in cash paid at closing, plus additional amounts payable to the seller, not to exceed $6.5 million in aggregate, that may be earned based on future performance and a one-time payment of an acquired accounts receivable remittance amount, in each case subject to adjustment as set forth in the purchase agreement.&nbsp;The transaction closed on March 31, 2025.

Asset Sales

QRHC

Quest Resource Holding Completes Sale Of Tenant-Direct Portion Of RWS Commercial Property Management Business To Lincoln Waste Solutions For $5M Cash, Plus Up To $6.5M In Performance-Based Payments

Loop Capital analyst Anthony Chukumba maintains RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) with a Hold and lowers the price target from $450 to $190.

Price Target

Analyst Ratings

Loop Capital Maintains Hold on RH, Lowers Price Target to $190

Macro Economic Events

Economics

Benzinga Market Summary: S&P, Nasdaq And Dow All Close Down Over 5% On US-China Tariff Tensions, Oil Tumbles On OPEC+ Production Hike Plans, Gold Falls

Destiny Tech100 Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXYZ#NYSE">DXYZ</a>) recently announced financial results for the quarter ended December 31, 2024. The fund reported a net asset value (NAV) of $6.44 per share of common stock, an increase from $5.32 per share at the end of the third quarter.
As of December 31, 2024, Destiny Tech100's investment portfolio had an aggregate fair value of approximately $70.9 million, including short-term investments. The fund maintains positions in a variety of privately-held technology companies.

DXYZ

Destiny Tech100 Q4 NAV $6.44 Up From $5.32 QoQ

Analysts' ratings for KKR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) over the last quarter vary from bullish to bearish, as provided by 8 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for KKR, presenting an average target of $164.25, a high estimate of $194.00, and a low estimate of $141.00. Highlighting a 2.16% decrease, the current average has fallen from the previous average price target of $167.88. 
<img src="https://www.benzinga.com/files/images/story/2025/1743796873_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of KKR's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Craig Siegenthaler</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$194.00</td>
<td>$214.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$141.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$156.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$150.00</td>
<td>$151.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$181.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Vikram Gandhi</td>
<td>HSBC</td>
<td>Raises</td>
<td>Hold</td>
<td>$173.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$151.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Kyle Voigt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$168.00</td>
<td>$170.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to KKR. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of KKR compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for KKR's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into KKR's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/KKR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on KKR analyst ratings.</a>
<h2>Get to Know KKR Better</h2>
KKR is one of the world's largest alternative asset managers, with $624.4 billion in total managed assets, including $505.7 billion in fee-earning AUM, at the end of September 2024. The company has two core segments: asset management (which includes private markets-private equity, credit, infrastructure, energy, and real estate-and public markets-primarily credit and hedge/investment fund platforms) and insurance (following the firm's initial investment in, and then ultimate purchase of, Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance).
<h3>A Deep Dive into KKR's Financials</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Decline in Revenue: Over the 3 months period, KKR faced challenges, resulting in a decline of approximately -26.81% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: KKR's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 35.17%, the company may face hurdles in effective cost management.
Return on Equity (ROE): KKR's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.72% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.31%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 2.15, caution is advised due to increased financial risk.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

8 Analysts Have This To Say About KKR

Across the recent three months, 15 analysts have shared their insights on Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $90.6, a high estimate of $105.00, and a low estimate of $70.00. This current average has increased by 3.82% from the previous average price target of $87.27. 
<img src="https://www.benzinga.com/files/images/story/2025/1743796865_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The analysis of recent analyst actions sheds light on the perception of Charles Schwab by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Smith</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$85.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Christopher Allen</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$102.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Devin Ryan</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$94.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>David Smith</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$91.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$91.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$95.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>David Smith</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$105.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Christopher Allen</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$96.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$89.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Christopher Allen</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$80.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Patrick Moley</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$65.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Charles Schwab. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Charles Schwab compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Charles Schwab's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Charles Schwab's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SCHW/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Charles Schwab analyst ratings.</a>
<h2>Delving into Charles Schwab's Background</h2>
Charles Schwab operates in brokerage, wealth management, banking, and asset management. It runs a large network of brick-and-mortar brokerage branch offices and a well-established online investing website, and it has mobile trading capabilities. It also operates a bank and a proprietary asset-management business and offers services to independent investment advisors. Schwab is among the largest firms in the investment business, with over $10 trillion of client assets at the end of 2024. Nearly all of its revenue is from the United States.
<h3>Charles Schwab: Financial Performance Dissected</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Charles Schwab displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 19.51%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Charles Schwab's net margin is impressive, surpassing industry averages. With a net margin of 32.22%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 4.45%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Charles Schwab's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.36%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 1.15, Charles Schwab adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SCHW

Expert Outlook: Charles Schwab Through The Eyes Of 15 Analysts

President Donald Trump&#8216;s <a href="https://www.benzinga.com/25/04/44646719/pdd-stock-drops-as-trumps-new-tariffs-threaten-chinese-e-commerce-giants" target="_blank" rel="noreferrer noopener">reciprocal tariffs on</a> April 2 (weighted average tariff of 18.2%, inclusive of a 10% baseline tariff and varying levels by individual country) have the potential to impact end demand trends and economic activity (both enterprise and consumer spending) for the remainder of the year, as per Goldman Sachs analyst Eric Sheridan.
Sheridan expects heightened uncertainty to slow corporate decisions between the second and fourth quarters of 2025, including a pullback in real-time investment areas (brand advertising, hiring) and management teams being more reactionary around other longer-dated investment areas (CapEx, R&amp;D, M&amp;A).
The visibility into AI CapEx&#8217;s return profile remains unclear, with broad enterprise adoption rates and consumer behavior shifts likely playing out over multiple years.
Also Read: <a href="https://www.benzinga.com/news/global/25/04/44645946/microsoft-halts-data-center-expansions-due-to-semiconductor-tariff-concerns-ai-overcapacity-fears" target="_blank" rel="noreferrer noopener">Microsoft Halts Data Center Expansions Due To Semiconductor Tariff Concerns, AI Overcapacity Fears</a>
The hyperscalers remain committed to this current CapEx cycle and noted little downside to fiscal 2025 CapEx guidance for Sheridan&#8217;s companies. Under that framework, the analyst would expect that investor debates about the level of CapEx investments will only intensify in the next 6 months.
Based on Sheridan&#8217;s conversations, investor fears up until April had been more anticipatory and reactive to data points in other industries. Through the end of March, the analyst still felt relatively comfortable that his coverage&#8217;s first-quarter operating performance reflected his current estimates.
Sheridan noted the main realized headwinds to his coverage in the first quarter as the overall slowdown of travel trends and the continued softening of the lower-end consumer concerning discretionary eCommerce goods.
Looking forward, Sheridan noted a rising debate about whether tariffs might push the US consumer away from goods toward more services.
For his coverage, uncertainty remains on whether service sectors like experiences, travel, and mobility are relative beneficiaries of sharply increased tariffs on goods.
Sheridan also noted tariffs potentially supporting a growing mix of non-discretionary goods in consumer baskets.
Based on the analyst&#8217;s recent industry conversations, advertising spending is likely to see some impact for the remainder of the year as companies weigh both lower potential end demand and higher input cost inflation. While overall ad spending tends to be a bit of a lagging indicator, the programmatic nature of digital makes certain digital channels and platforms more volatile and subject to real-time pullbacks.
Within digital, Sheridan noted platform exposure to certain pockets of ad spend will dictate the level of headwinds each company sees for the remainder of the year.
On TikTok US, press reports indicate an increasing likelihood of some resolution to keep TikTok operational in the US. Even with a potential resolution, Sheridan&#8217;s channel checks point to a pullback from peak levels of both users, engagement, and, more materially, ad spending on the platform as the ongoing uncertainty has weighed on advertiser demand.
At a high level, tariff impacts on eCommerce businesses are largely an output of the volume and cost of goods sold (COGS) exposure by geography, how much price can be passed on to consumers, the resulting decrease in units (elasticity), how much margin can be extracted from suppliers, and the level of substitution of suppliers and geographies.
In a companion note, Sheridan exhibited an illustrative framework for Amazon.com Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) 1P business concerning these factors.
As a notable offset, the closing of the de minimis exemption for China likely removes competitive pressures from the broader US eCommerce industry. The recent wave of China-based exporters (PDD Holdings Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pdd#NASDAQ">PDD</a>) Temu and TikTok Shop, and others) that have been heavily reliant on the exemption now face sizable tariffs.
Although these companies have flattened out their U.S. ad spending in recent quarters, Sheridan still anticipates slight headwinds to advertising trends due to less dense auctions if these players leave the market.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44633991/blackberrys-qnx-secure-comms-growth-weighed-down-by-tariff-uncertainties-government-election-shifts-analyst" target="_blank" rel="noreferrer noopener">BlackBerry&#8217;s QNX, Secure Comms Growth Weighed Down By Tariff Uncertainties, Government Election Shifts: Analyst</a></li>
</ul>
Image: Shutterstock

AMZN

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Tariffs To Impact End Demand: Goldman Sachs Analyst Expects Drag On Corporate Spending, Hiring

Press Releases

Riot Announces January 2025 Production and Operations Updates

Crypto Mining Stocks Decline Amid AI Market Volatility

Small Cap

Riot Announces Fourth Quarter and Year-End 2024 Earnings Conference Call

Crypto Stocks Rally as Bitcoin Hovers Near $100K

Riot Platforms Announces Changes to Its Board of Directors and Provides Update on Formal Evaluation of AI/HPC Uses

Riot Platforms Reports Full Year 2024 Financial Results, Current Operational and Financial Highlights

Riot Announces February 2025 Production and Operations Updates

Riot Platforms Announces Entry into Non-Binding Term Sheet to Acquire Certain Assets of Rhodium and Settlement Agreement

Tech Stocks See Historic Gains in 2024 Thanks to Crypto and AI

Riot Announces March 2025 Production and Operations Updates

COIN

LINE

MARA

MSTR

NVDA

PCOR

TSX:WNDR

WONDF

Agilysys

C3.ai

Alkami Technology

Alarm.com Holdings

Asana

AvePoint

BlackLine

Blackbaud

Braze

Cleanspark

Core Scientific

Sprinklr

Diginex

DoubleVerify Holdings

EverCommerce

Five9

Life360

Ncino

Pony AI Inc. - American Depositary Shares

Pony AI

D-Wave Quantum

RingCentral

SoundHound AI, Inc. - Class A Common Stock

SoundHound AI

Tuya Inc. American Depositary Shares, each representing one Class A Ordinary Share

Tuya

Clear Secure

Zeta Global Holdings Corp. Class A Common Stock

Zeta Global Holdings

JP Morgan

Roth MKM

Cantor Fitzgerald

Piper Sandler

Needham

Riot Blockchain

Screenshot 2025-02-14 at 11.00.11 AM

CLSK

FUFU

How BitFuFu&#39;s 1GW Global Capacity Expansion Plan Can Help Move Crypto Into A New Landscape

Screenshot 2024-11-15 at 7.42.11 PM

BTDR

BitFuFu Posts Double-Digit Third Quarter Revenue Growth In A Challenging Market

Untitled design - 2024-08-30T174008.310

BitFuFu Posts 70% Revenue Growth And Outlines Strategic Expansion – Company Expects Continued Growth Amid Market Volatility

Screenshot 2024-06-26 at 5.30.28 PM

Three Bitcoin Players You May Want To Watch In The Next Potential Bull Cycle

Screenshot 2024-05-29 at 5.42.06 PM

BitFuFu Q1 Earnings: Adjusted EBITDA Up 430.9% To $49.4 Million On Revenue Growth Of 149%, Cash Position Rises To $163.7 Million

Screenshot 2024-04-12 at 5.28.51 PM

Bitdeer Releases Full-Year Results For 2023 – Revenue Up And Forecast For Continued Growth

Screenshot 2024-03-13 at 5.41.37 PM

Bitdeer Creates First-Generation Bitcoin Mining Chip In Major Step To Becoming The First Fully Integrated Miner

Comments

Riot Platforms

Riot Platforms (RIOT) オプション

Riot Platforms (NASDAQ:RIOT) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル